Please login to the form below

Not currently logged in
Email:
Password:

Double chin

This page shows the latest Double chin news and features for those working in and with pharma, biotech and healthcare.

Allergan adds Zeltiq to M&A roster in $2.48n deal

Allergan adds Zeltiq to M&A roster in $2.48n deal

Other deals in the aesthetics sector include Allergan's $2.1bn purchase of Kythera in 2015, bringing in double chin-reducing therapy Kybella (deoxycholic acid), and the takeover of regenerative medicine

Latest news

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... Kybella. submental contouring (double chin).

  • Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera Allergan inks $2.1bn deal to buy cosmetic drug firm Kythera

    Company will add Kythera’s double chin therapy Kybella to its portfolio. ... Botox manufacturer Allergan has extended its position in the growing cosmetic or 'aesthetic' pharmaceuticals sector with the purchase, which adds Kythera's double chin therapy

  • Kythera bags FDA approval for double chin therapy Kythera bags FDA approval for double chin therapy

    Comes as cosmetics industry sees major growth.  . The US FDA has approved the first drug to treat submental fat in adults - otherwise known as a double chin. ... Prior to the approval of Kybella the only treatment available for double chin was

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    fat (double chin). ... Kythera Biopharmaceuticals/ Allergan. Rx aesthetic medicine products - incl Kybella  for double chin (FDA approved).

  • Pharma deals during March 2014 Pharma deals during March 2014

    In addition, Five Prime could receive up to $300m in future development, regulatory and sales-based milestones per collaboration target, as well as tiered mid-single-digit rising to ... US and Canada. ATX-101 is a proprietary injectable formulation of a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics